Suppr超能文献

1997年《美国食品药品监督管理局现代化法案》的药品条款:已过去一年且仍在持续。

Pharmaceutical provisions of the FDA Modernization Act of 1997: one year and counting.

作者信息

Binder G M

机构信息

Amgen, One Amgen Center Drive, Thousand Oaks, CA 91320-1789, USA.

出版信息

Curr Opin Biotechnol. 1999 Jun;10(3):303-6. doi: 10.1016/S0958-1669(99)80054-8.

Abstract

The FDA Modernization Act of 1997 represents a notable public policy achievement that was conceived not out of crisis, but rather out of a shared commitment that the FDA can both protect patient health (by assuring drugs are safe and effective) and promote public health (by being given additional resources and new procedural efficiencies to accelerate the review of applications for new medicines). The FDA is conscientiously implementing this important new law, but there are areas where more work is required. On balance, the prospects are that this law will help usher in a much improved era for patients.

摘要

1997年的《美国食品药品监督管理局现代化法案》是一项显著的公共政策成就,它并非因危机而产生,而是源于一种共同的信念,即美国食品药品监督管理局既能(通过确保药品安全有效)保护患者健康,又能(通过获得更多资源和新的程序效率来加速新药申请审查)促进公众健康。美国食品药品监督管理局正在认真执行这项重要的新法律,但仍有一些领域需要进一步努力。总体而言,这项法律有望为患者带来一个大为改善的时代。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验